Ars.els-cdn.com
Table S2. Comprehensive list of restricted medicationsMedications allowed with restrictionsRecommendationsAcid-reducing agents (H2 receptor antagonists, proton pump inhibitors)Acid reducing agents should be administered at least 2 hours after study drug administrationWhenever possible, an H2 receptor antagonists (except cimetidine) or antiacids is preferred over a proton-pump inhibitorH2 receptor antagonists (e.g. famotidine or ranitidine) should be given from 2 to 12 hours after administration of the study drug at a dose that does not exceed doses comparable to famotidine 40 mg dailyAntiacids (e.g. aluminium hydroxide, calcium carbonate, magnesium carbonate, magnesium hydroxide or bismuth subsalicylate) should be given at least 4 hours after administration of study medicationProton pump inhibitors (such as omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole, or delansoprazole) should be given approximately 3 hours after administration of study drug and doses should not exceed the dose comparable to omeprazole 20 mg dailyLipid-lowering agentsThe maximum recommended daily doses:Atorvastatin: 40 mg, simvastatin: 10 mg, lovastatin (CYP3A4 substrates): 40 mg, pravastatin (CYP3A4 substrate and weak CYP2C8 inhibitor): 40 mg, and rosuvastatin (BCRP substrate): 10 mg Pitavastatin is allowed without dose restriction. Patients should be monitored for symptoms of myopathy or liver injuryPDE5 inhibitorsThe recommended starting doses for the following CYP3A4 substrates are as follows: Sildenafil 25 mgTadalafil 2.5 mgVardenafil 2.5 mgBCRP, breast cancer resistance protein; CYP, cytochrome P450; CVC, cenicriviroc; PDE5, phosphodiesterase type 5 ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.